论文部分内容阅读
目的探讨(125)~I粒子植入联合支气管动脉化疗栓塞治疗非小细胞肺癌(NSCLC)的临床应用价值。方法 34例NSCLC患者,进行支气管动脉化疗栓塞治疗16例(A组),(125)~I粒子植入联合支气管动脉化疗栓塞治疗18例(B组),治疗后进行疗效评价及生存分析。结果 A、B两组治疗有效率分别75%和83.3%;中位生存时间分别为为7.4个月和12.6个月;6、12、24个月生存率分别为62.5%、37.5%、0%和83.3%、55.5%、22.2%,两组中位生存时间及6、12、24个月的生存率差异有统计学意义(P<0.05)。结论 (125)~I粒子植入联合支气管动脉化疗栓塞是NSCLC的一种有效治疗方法,可以延长患者的生存时间。
Objective To investigate the clinical value of (125) ~ I seed implantation combined with bronchial artery chemoembolization in the treatment of non-small cell lung cancer (NSCLC). Methods Totally 34 patients with NSCLC were treated with bronchial artery chemoembolization (group A), (125) I seed implantation combined with bronchial artery chemoembolization (group B), and the therapeutic effect and survival analysis were performed after treatment. Results The effective rates of treatment A and B were 75% and 83.3% respectively; the median survival time was 7.4 months and 12.6 months respectively; the survival rates at 6, 12 and 24 months were 62.5%, 37.5% and 0% And 83.3%, 55.5% and 22.2%, respectively. The median survival time and the survival rates at 6, 12 and 24 months were statistically significant (P <0.05). Conclusion (125) ~ I particle implantation combined with bronchial artery chemoembolization is an effective treatment for NSCLC, which can prolong the survival time of patients.